$158 Million

TORL BioTherapeutics

Capital Markets Advisory

Exclusive Financial Advisor, April 2023

TORL BioTherapeutics
Series B Private Equity Placement

TORL BioTherapeutics LLC is a clinical-stage biopharmaceutical company with the objective of developing novel, antibody-based therapeutics to transform the lives of cancer patients. Its lead candidate, TORL-1-23, is a CLDN6-directed ADC developed for patients across multiple cancer types. The Company also has two other clinical-stage programs; an ADC and mAb targeting CLDN 18.2. Additionally, TORL is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications with a high unmet medical need. TORL is headquartered in Los Angeles.

More Like This

Jan 2024
$250 Million

Follow-on Offering

Bookrunner

View Details >
Jan 2024
$113 Million

Follow-on Offering

Bookrunner

View Details >
Jan 2024

Frontier Service Partners, a portfolio company of Imperial Capital, has been acquired by Apex Service Partners, a platform of Alpine Investors

Exclusive Financial Advisor

View Details >